Cancer Institute– A national cancer institute
designated cancer center

Sally Arai

Back to Profile

Publication Details

  • Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.

    Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H. Cytotherapy. 2008; 10 (6): 625-32

    Renal cell cancer and malignant melanoma are two types of cancer that are responsive to immunotherapy. In this phase I dose-escalation study, the feasibility of large-scale expansion and safety of administering ex vivo-expanded NK-92 cells as allogeneic cellular immunotherapy in patients with refractory renal cell cancer and melanoma were determined.

    PubMedID: 18836917

Stanford Medicine Resources:

Footer Links: